局限期小细胞肺癌同步放化疗联合阿替利珠单抗的III期试验
NRG Oncology/Alliance LU005是一项开放标签、国际III期试验,评估在同步放化疗基础上联合阿替利珠单抗治疗局限期小细胞肺癌(LS-SCLC)。主要终点总生存期(OS)在单纯放化疗组为36.1个月,联合组为31.1个月(HR 1.03,95%CI 0.80-1.32),无进展生存期(PFS)和远处转移无生存期(DMFS)亦无显著改善,且未观察到非预期安全性信号。结论为同步及辅助阿替利珠单抗联合放化疗未改善LS-SCLC患者生存。
要点
- 同步放化疗联合阿替利珠单抗未改善局限期小细胞肺癌的总生存期。
- 联合组中位OS为31.1个月,单纯放化疗组为36.1个月,HR 1.03。
- 联合治疗未观察到非预期安全性信号。
核心结论
- 同步及辅助阿替利珠单抗联合放化疗未改善局限期小细胞肺癌患者的生存。
研究设计与样本
- NRG Oncology/Alliance LU005为开放标签、国际III期随机试验(NCT03811002)。
- 入组患者为局限期小细胞肺癌(Tx-IV, N0-3, M0),ECOG PS 0-2,注册前接受1周期铂/依托泊苷化疗。
- 患者随机分配至单纯放化疗组或放化疗联合阿替利珠单抗组(同步及辅助,1200 mg 每3周一次,最多17周期)。
- 分层因素包括化疗选择(顺铂 vs 卡铂)、放疗分割方案(66 Gy 每日一次 vs 45 Gy 每日两次)、性别和PS(0/1 vs 2)。
- 主要终点为总生存期(OS),次要终点包括研究者评估的无进展生存期(PFS)、客观缓解率、局部控制及远处转移无生存期(DMFS)。
主要发现
- 单纯放化疗组中位OS为36.1个月(95%CI 28.1-42.5),联合阿替利珠单抗组为31.1个月(95%CI 28.5-44.7),HR 1.03(95%CI 0.80-1.32)。
- 单纯放化疗组中位PFS为11.4个月(95%CI 10.3-13.2),联合组为12.1个月(95%CI 10.9-15.2),HR 0.98(95%CI 0.79-1.22)。
- 单纯放化疗组中位DMFS为13.0个月(95%CI 11.3-18.2),联合组为16.8个月(95%CI 12.1-21.6),HR 0.96(95%CI 0.76-1.21)。
- 同步阿替利珠单抗未观察到非预期安全性信号。
临床怎么用
- 对于局限期小细胞肺癌,同步放化疗联合阿替利珠单抗不应作为常规推荐。
- 该结果不支持在LS-SCLC的同步放化疗中常规加入阿替利珠单抗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: NRG Oncology/Alliance LU005 (ClinicalTrials.gov identifier: NCT03811002) tested the addition of atezolizumab to concurrent chemoradiation (CRT) in this open-label, phase III international trial. METHODS: Patients with limited-stage small cell lung cancer (LS-SCLC), stage Tx-IV, N0-3, and M0 with Eastern Cooperative Group performance status (PS) 0-2 received one cycle of chemotherapy (platinum/etoposide) before study registration and were randomly assigned to CRT alone versus CRT plus concurrent and adjuvant atezolizumab, 1,200 mg once daily, every 3 weeks until investigator-assessed progression or intolerable side effects for a maximum of 17 cycles. Patients were stratified by choice of chemotherapy (cisplatin v carboplatin), radiation fractionation schedule (66 Gy once daily v 45 Gy twice daily), sex, and PS (0/1 v 2). The primary end point was overall survival (OS). Secondary end points included investigator-assessed progression-free survival (PFS), objective response rate, local control, and distant-metastasis-free survival (DMFS). RESULTS: patients were randomly assigned from May 2019 to December 2023. The median OS was 36.1 months (95% CI, 28.1 to 42.5) for the CRT-alone arm and 31.1 months (95% CI, 28.5 to 44.7) for the CRT + atezolizumab arm, respectively (hazard ratio [HR], 1.03 [95% CI, 0.80 to 1.32]). The median PFS was 11.4 months (95% CI, 10.3 to 13.2) for the CRT-alone arm and 12.1 months (95% CI, 10.9 to 15.2) for the CRT + atezolizumab arm, respectively (HR, 0.98 [95% CI, 0.79 to 1.22]). The median DMFS was 13.0 months (95% CI, 11.3 to 18.2) for the CRT-alone arm and 16.8 months (95% CI, 12.1 to 21.6) for the CRT + atezolizumab arm (HR, 0.96 [95% CI, 0.76 to 1.21]). No unexpected safety signals with concurrent atezolizumab were observed. CONCLUSION: Concurrent and adjuvant atezolizumab with chemoradiation did not improve survival in patients with LS-SCLC.
引用
- Higgins KA, Hu C, Ross HJ, et al. Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. J Clin Oncol. 2026. PMID: 41529214. doi:10.1200/JCO-25-01569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。